AbCellera Biologics Inc vs Wendys Co — how do they compare? AbCellera Biologics Inc trades at $10.19 (market cap $2.99B), while Wendys Co trades at $8.5 (market cap $1.44B). The key difference: AbCellera Biologics Inc is far larger — about 2.1× Wendys Co's market cap, and Wendys Co pays a 3.71% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WEN | |
|---|---|---|
Market Cap | $2.99B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $10.68 |
52-Week Low | $2.78 | $6.17 |
Enterprise Value | $2.58B | $5.17B |
Dividend Yield | — | 3.71% |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
WEN trades at $8.595, up 17.74% in 24 hours, with a neutral technical signal. Recent Q2 2026 EPS of $0.18 beat expectations, but revenue trends are flat and net income margin declined to 5.72% in 2025. The company cut its dividend and withdrew 2026 guidance amid a strategic turnaround under new leadership, facing traffic declines and loss of its No. 2 U.S. burger chain position to Burger King.
Outlook is cautious; the dividend cut frees cash for restructuring, but execution risks are high. Valuation appears reasonable with a P/E of 11.44, though high debt and competitive pressures pose significant headwinds. Analyst consensus is mixed, with 62.75% hold ratings reflecting uncertainty around the turnaround plan's success.
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →